Injectable Drug Delivery

Advances in technology for pens, auto-injectors, large volume pumps, patch pumps, needle-free, pre-filled syringes and other parenteral methods.

28-29 Mar 2019

GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 15 Feb

Book now

Conference Overview

Injectable drug delivery is considered one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, as well as the improved patient experience. The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.

This seminar has been designed for all those working in the industry to discover the next generation of injectable drugs and devices and get an update on the latest trends, technologies and applications. Attending this event will provide a great opportunity to network with industry leaders, as well as like-minded professionals, to share common experience and best practice.

Attending this two-day seminar, presented by key industry experts, will:

  • Give you a valuable update on the advances in injection technology and drug delivery
  • Present you with up-to-date information on the latest market trends and opportunities for your organisation
  • Provide you with an opportunity to develop significant business partnerships

Newly updated programme for 2019 below – book your place !

 

Book both

This meeting runs back-to-back with Pre-filled Syringes and there is a further £200/€280 discount when booked together with this programme.

To register on both events click HERE

To find out more call Customer Services on +44 (0)20 7749 4730 or e-mail info@management-forum.co.uk

Previous Exhibitors Include:

3PInnovation logo

Harro Hofliger logo

Owen Mumford logo

ODD logo

Advanex logo

Exhibition opportunities are available. Please contact Customer Services on +44 (0)20 7749 4730
or contact us through our contact form.

Benefits in attending

  • Hear the latest trends in injectable drug delivery
  • Know what’s in development for large volume and patch pump technology
  • Keep abreast of market opportunities
  • Understand the latest technologies using parenteral methods
  • Clarify the importance of human factor studies and compliance monitoring
  • Comply with the latest regulatory guidance and standards
  • Meet other medical device and pharmaceutical professionals in the parenteral market

Who should attend

This conference will be of particular interest to:
Scientists and management in medical devices, pharmaceutical and biotechnology companies working in parenteral delivery. Personnel responsible for device programmes, product development, regulatory affairs and product lifecycle management will find this event beneficial. Previous delegates include: Directors, Senior Executives in R&D, Head of Device Departments, Combination Products Specialists, Drug Delivery Managers, Business Development Executives, Product Development Managers and those in Project Co-ordination and Marketing roles.

Programme day one

Chair’s welcome and introduction
Dr Gregory Berman

The evolving market for self-injection devices, differentiation through patient-friendly drug delivery devices

  • Market overview of parenteral drug delivery containers and devices
  • Evolving patient, market and regulatory expectations
  • Improved patient health and adherence through injectables
  • Emerging trends for novel drug delivery systems
  • Small volumes vs large volumes – where is it going?
  • Benefits of platform technology: faster time to market
    Dr Thomas Schönknecht

Assessing injection site pain

  • Understanding how to measure pain and tolerability during injection and how to interpret the results
  • Summary of recent clinical investigations of high-volume injections
  • Impact on the design and selection of wearable drug delivery devices
    Chris Muenzer

Discussion session

Challenges with high-volume and high-viscous drug formulations

  • Understand device and formulation landscape (mapping of potential design avenues not existing device landscape)
  • Selection criteria and considerations for both sourced or internally designed devices
  • Pitfalls and issues to be aware of with HVHV devices
  • Future gazing at device development trends
    Uri Baruch

Developing delivery solutions for advanced biologics

  • Cell line development
  • Sourcing
  • Scale up
  • Technology transfer
  • Process analytic development
    Shruthi Vidyasagar

Discussion session

Pre-filled syringes over time

  • Evolution of processes and equipment
  • Evolution of components
  • Evolution of application and application systems
    Dr Andreas Rothmund

Using polymeric PDC technology to improve auto-injector design

  • The benefits of polymeric primary drug container (PDC) technology for the user and drug
  • PDC components configured freely, resolving issues typically seen with glass-based systems
  • How an integrated approach to device design reduces the impact on the user without compromise
  • Oval’s subcutaneous platform, Sumalen Ovali, and how it embodies this integrated philosophy to device design
  • A patient-centric device for delivery of Sumatriptan to migraine and cluster headache sufferers
    Suki Whitehall

Discussion session

Connected needle-free drug delivery: innovative technology to differentiate your brand

  • The rapidly growing availability of monoclonal antibody and biologics therapies for chronic disease therapy
  • Why compliance and ease of use remain issues for these treatments
  • Review of recent attempts to connect drug delivery devices for biologics and lessons learned
  • Needle-free connected drug delivery systems
  • How interactivity and automated injection tracking could drive patient adherence and outcome
    Barb Taylor

Interactive panel discussion: opportunities for connectivity with hand-held injection devices
Moderator: Dr Gregory Berman
Panellists: Dr Thomas Schönknecht, Chris Muenzer and Barb Taylor

Networking drinks reception

Programme day two

Review of day one Dr Gregory Berman

Demand for large volume injectors for 2-10 ml injection volumes

  • Current trends for large volume injectors above 1ml
  • YpsoDose patch injector update
  • YpsoDose : usability and technical aspects
    Ian Thompson

Challenges of medical delivery in acute and chronic care settings – implications for delivery design

  • Clinical challenges for chronic versus acute care settings
  • Patient transition from acute care to step-down facilities; long-term care and home care settings
  • Commercial, ambulatory pump drug delivery systems; pros and cons of current devices
  • Opportunities for improving therapy
  • Wearable devices, patient-controlled analgesia (PCA), drug delivery via indwelling venous access devices (eg PICCs, CVCs, Midlines)
    __

Discussion session

From the treatment chair to the sofa – innovative concept for wearable injection

  • New innovative approach to enable home care and address several market trends
  • Usability of a new dimension
  • Cutting-edge technology to benefit the patient
  • Opportunities for injectable drug delivery alternatives
    Tsachi Shaked

Update on the Ominpod device

  • How the technology works
  • Benefits to the patient
  • Personal diabetes management (PDM)
  • Continuous innovation for the diabetes community
    Dominic Hulton

Discussion session

The EU regulatory framework for injectable delivery systems

  • Classification – the importance of getting it right from the start
  • Implications of the new EU Medical Device Regulation (EU) 2017/745 and Article 117 for drug delivery systems
  • Essential considerations for injectable medicinal products
    Mark Chipperfield

Planned changes to the 11608 series of ISO standards and their implications on device design

  • How are large volume injectors different from infusion pumps?
  • Important changes proposed in the updates to the 11608 series
  • How these changes will impact on your device design
  • Verification of device performance
    Stephen Augustyn

Interactive panel discussion: opportunities with wearable and large volume injectors
Moderator: Dr Gregory Berman
Panellists: Ian Thompson and Stephen Augustyn

Chair’s closing remarks

End of seminar and refreshments

Presenters

Andreas Rothmund

Dr. Andreas Rothmund is Qualified Person at Vetter Pharma-Fertigung in Ravensburg, Germany, an independent contract manufacturer specialised in the aseptic production of pre-filled application systems. He started his industrial career in 1985 as a lab manager. After two years he took over production responsibility for a German company specialised in eye drops and eye ointments, a position he held for nearly eight years. He joined Vetter in 1994, where he has held several positions, including Head of Production for one of Vetter’s aseptic production units. He holds a degree in organic chemistry from the University of Constance, Germany.

Gregory Berman

Gregory Berman is an Independent Consultant and Director of Cantab Innovations Ltd. Previously he was Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences. He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically. For example he:
Led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.
Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.

Thomas Schoenknecht

Dr Thomas Schoenknecht, is Head of Research and Development Drug Product Services, Lonza, Switzerland, previously he was Executive Director, Business Development at SHL Group, with responsibility for global Business Development, Key Account Management and new Technology Evaluation within SHL’s Medical division.

He has over 20 years’ experience in pharmaceutical industry in various leading roles in project management, research & development and business development. Prior to joining SHL in 2013, Thomas worked at Schott Pharmaceutical Packing Division where he was heading the global Key Account Organization with a specific focus on new product developments addressing the customer needs.

Thomas previously worked at Amgen Inc in California as Director Drug Product and Device Development overseeing and managing Amgen’s global drug delivery container projects and interfacing Amgen’s drug delivery device platforms. Prior to being engaged with Amgen he was heading the Research & Development activities at Gerresheimer’s Pharmaceutical Packing Division and was leading the Product Management and Business Development activities of this division for sterile drug delivery solutions.

Thomas has a Ph.D. in Biophysical Chemistry from the Max-Planck-Society and the University Goettingen, Germany and a Master’s degree in Chemistry from the University Goettingen. He is a frequent speaker, moderator and committee member at conferences regarding drug delivery and packing material science; Thomas was heading the PDA interest group for prefilled syringes and being active as member in various DIN ISO committees regarding primary packaging materials and drug delivery devices.

Ian Thompson

Ian has been Vice President Business Development, Delivery Systems with Ypsomed AG since 1995. He has had a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Following the successful development and launch of a range of new pen and autoinjector custom products, Ypsomed Delivery Systems’ continues to focus on the development of next generation pen, autoinjector and bolus injector technologies.

Mark Chipperfield

Mark serves as an independent consultant to the Pharma and Medical Device industries via his company Corvus Device Ltd. He has over twenty years of experience in Medical Device, Drug Delivery Device and Combination Product Development, Operations and Regulatory/Quality Compliance – from a range of roles with GSK, sanofi-aventis, Novartis and F. Hoffmann-La Roche.Through his career to date he has been heavily involved in development of medical devices for combination products in several forms: syringes, pen injectors, auto-injectors, patch injectors, solution/suspension inhalers, multi-dose disposable and reusable dry powder inhalers, convenience kits, dispensers and special purpose applicators. He has performed numerous due diligence and technical evaluations of novel delivery technologies; developed products through the full design control phases to market; and maintained marketed products. Mark is a veteran of several successful IND/CTA/NDA/BLA/MAA submissions and approvals that have included drug delivery devices.He has experienced many of the challenges associated with delivery device development and device product maintenance within large pharmaceutical companies and implemented Medical Device development guidance, quality systems and business processes.

Uri Baruch

Uri heads up the drug delivery sector within CDP, leading a variety of design projects including an award-winning needle safety device, an emergency auto-injector, a pen injector packaging design for delivery devices and inhalation products. These projects included compiling design history files and led to successful submissions to both the FDA and the EMA. Uri has worked in industries including aerospace and defence, medical devices, automotive and inkjet. He has extensive knowledge of design for manufacturing and process design, and was involved in setting up several production lines around the world in the automotive inkjet and medical devices sectors.

Tsachi Shaked

Tsachi Shaked, MBA, Chief Marketing and Business Development Officer at E3D (Elcam Drug Delivery Devices) a subsidiary of Elcam Medical. Tsachi graduated with a Master in Business Administration (MBA) with experterise in Marketing from Bar-Ilan University in Ramat-Gan, Israel. As part of the company’s portfolio, Tsachi is deeply involved with the development of the new version of drug delivery devices that includes connectivity and electronic applications. Tsachi has been with the company from 2006.

Steve Augustyn

Steve is head of mechanical engineering for Team Consulting; an award-winning, specialist medical device design consultancy based in Cambridge. Before joining Team nine years ago, Steve worked as a freelance designer for multinational companies including five years working for Glaxo Smith Kline. Most of Steve’s technical work is focussed on drug delivery devices and through this experience he has worked as a member of ISO TC-84 developing the 11608 series of standards over the past five years. A graduate of Loughborough University, Steve also lectures undergraduates on the medical device development process.

Christopher Muenzer

Chris Muenzer is a Senior Device Technology Manager at Novartis in Basel, Switzerland. He has almost 20 years of development experience with a focus on drug delivery devices and has filed several patents in the field. At Novartis, Mr. Muenzer leads a team supporting injectable delivery systems for Novartis’ diverse portfolio of drugs. In addition to his work at Novartis, he is active on the ISO working group for injection devices. Mr. Muenzer holds a BSME from Carnegie Mellon University in Pittsburgh, Pennsylvania in the US.

Suki Whitehall

Sukie Whitehall, Device Development Engineer with Oval Medical Technologies. She is a young Mechanical Design engineer with a background in Physics, who tailored her education and career to specialise in Medical devices. She has worked on IVD’s, point-of-care diagnostics, home diagnostics and more recently drug delivery. Sukie is focused on providing user friendly devices that not only work perfectly every time – but fit seamlessly into people’s lifestyles. She believes that with good design, a shift can be facilitated in healthcare from surgeries into the home – and hopes this will help to alleviate the pressures on the public health services.

Dominic Hulton

Dominic Hulton, Vice President of Marketing for Europe Insulet, UK.

Shruthi Vidyasagar

Shruthi Vidyasagar, Device Development Lead, GSK.

Barb Taylor

Barbara Taylor leads the marketing team at Portal Instruments. With over 20 years experience in health tech strategy and marketing, she brings to Portal expertise in healthcare software development, new product introduction, lifecycle and service strategy, and business model innovation. Prior to Portal Instruments, Barbara was at a number of large and small firms including Philips Healthcare and Mercer Management Consulting. Barbara holds an MBA from the Kellogg Graduate School in Evanston, IL and a BS in biology from the University of Michigan in Ann Arbor, MI.

Book now

28-29 Mar 2019
28-29 Mar 2019 Cavendish Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 15 Feb
Enrol now

You may also be interested in

Previous customers include...

  • 3P Innovation Ltd
  • ABBOTT GmbH & Co KG
  • Alexion Pharmaceuticals Inc
  • Artsana S.p.A.
  • Battelle
  • Biogen
  • Cantab Innovations
  • Carpmaels & Ransford Services Ltd
  • F. Hoffmann-La Roche AG
  • Future Injection Technologies Limited
  • Genentech Inc
  • GlaxoSmithKline
  • Grunenthal GmbH
  • International Device Solutions
  • LEO Pharma
  • Novartis Pharma AG
  • PA Consulting
  • PA Consulting Group
  • PharmaJet Inc.
  • PRESSPART GmbH & Co. KG
  • Robert Bosch GmbH
  • S3 Group
  • Sindolor Medical Ltd
  • SteadyMed Therapeutics Inc
  • Team Consulting Ltd
  • Terumo Europe NV
  • Teva Pharmaceuticals Runcorn
  • Texchem-Pack (M) Bhd
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • West Pharmaceutical Services Cornwall Ltd

Well worth the time

David Haase, Senior Manager Device Development, Genentech

Good conference. Will most likely come again.

Thomas Mayer, Intl. Key Account Manager, Sonceboz SA

Excellent!

Mindy Katz, Product Manager, Sorrel Medical

Very good

Roland Marshall, Account Manager, Owen Mumford Ltd